 Imara Inc NASDAQ: IMRA shares are falling after interim analyses of its Ardent Phase 2b trial of tovinontrine IMR-687 in sickle cell disease SCD and Forte Phase 2b trial in beta-thalassemia. Data from the sickle cell disease study interim analysis demonstrated that. 